EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML

Matilda Arvidsson Kvissberg, Christer Nilsson, Niklas Landberg, Albin Österroos, Aristea Papageorgiou, Bertil Uggla, Vladimir Lazarevic, Stefan Deneberg, Martin Jädersten

Annals of Hematology · 23.10.2026 · 105 (11)

DOI: 10.1007/s00277-026-07297-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 23.10.2026. Verfasst von Matilda Arvidsson Kvissberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden. matilda.arvidsson.kvissberg@ki.se. Hauptthemen laut MEDLINE: Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Bridged Bicyclo Compounds, Heterocyclic. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Swedish Cancer Society, Center for Innovative Medicine, The Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FLT3- mutated acute myeloid leukemia (AML) is associated with high relapse rates and treatment resistance. Triplet therapy with azacitidine (AZA), venetoclax (VEN), and the FLT3 inhibitor gilteritinib (GILT) yields high response rates but is limited by myelosuppression and infections. We conducted a multicenter retrospective study of 29 FLT3 -mutated AML patients treated with GILT-triplets. The primary endpoint was overall survival (OS); secondary endpoints event-free survival (EFS) and time to neutrophil and platelet recovery. Patients received one of three regimens: concomitant triplet therapy (Group 1); concomitant AZA + VEN followed by concomitant VEN+GILT (Group 2); or overlapping AZA + VEN followed by GILT monotherapy (Group 3). For the entire cohort median OS was not reached after more than five years of follow-up. High response rates were observed across all schedules. Limiting concomitant exposure reduced myelosuppression and decreased infectious complications compared with full triplet therapy. Median OS was not reached in Groups 1 and 2 after three years, whereas Group 3 had a median OS of 18 months. Median EFS was 40.5 months in Group 1 and was not reached at five years in Group 2, compared with 11.5 months in Group 3. Our data suggest that reducing the duration of triple-drug overlap may improve tolerability without compromising clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, Heterocyclicfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationPyrazinesSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

AMLAzacitidineGilteritinibTargeted therapyVenetoclax

Substanzen

Aniline CompoundsAzacitidineBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPyrazinesSulfonamidesvenetoclax

Autor:innen und Institutionen

  • Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden. matilda.arvidsson.kvissberg@ki.se.
  • Department of Hematology, Karolinska University Hospital, Stockholm, Sweden. matilda.arvidsson.kvissberg@ki.se.
  • Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.

Förderung

  • The Swedish Cancer Society
  • Center for Innovative Medicine
  • The Swedish Research Council
  • The Swedish Blood Cancer Association

Zitieren

APA

Arvidsson Kvissberg, M., Nilsson, C., Landberg, N., Österroos, A., Papageorgiou, A., Uggla, B., Lazarevic, V., Deneberg, S., & Jädersten, M. (2026). Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07297-2

Vancouver

Arvidsson Kvissberg M, Nilsson C, Landberg N, Österroos A, Papageorgiou A, Uggla B, et al. Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07297-2

BibTeX
@article{ArvidssonKvissberg2026,
  author = {Arvidsson Kvissberg, Matilda and Nilsson, Christer and Landberg, Niklas and Österroos, Albin and Papageorgiou, Aristea and Uggla, Bertil and Lazarevic, Vladimir and Deneberg, Stefan and Jädersten, Martin},
  title = {Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07297-2}
}
Kostenlos starten →